Last checked at 
(Alliance News) - Angle PLC said on Friday a new peer-reviewed study shows potential for its Parsortix system to be used in immunotherapy treatment selection.
The Surrey, England-based medical diagnostics company said that the study published by Edith Cowan University, Perth, Australia shows the potential for Parsortix to help select patients who would respond well to immunotherapy treatments in clinical trials.
Blood from 16 ovarian cancer patients was processed using Parsortix instrument which caught circulating tumour cells. The CTCs were stained with multiple markers to determine their phenotype and PD-L1 status. The findings advanced knowledge on the associations between phenotype and PD-L1 status.
The current likelihood of patients responding to PD-L1 or PD-1 inhibitors is low, and non-responders risk hyper-progressive disease, and drug toxicity with immune-related adverse events. Therefore, the staining procedure on CTCs isolated by Parsortix has the potential to help evaluate compatible biomarkers in patients for clinical trials.
Angle Founder and Chief Executive, Andrew Newland, commented: "We are pleased to report on this promising pilot data showcasing the utility of the Parsortix system for the unbiased isolation of multiple subsets of CTCs in ovarian cancer patients. Whilst ctDNA is increasingly used for the stratification of cancer patients, it is unable to provide insight into PD-L1 status. In contrast, CTCs can provide PD-L1 status. Angle is currently in the process of validating a PD-L1 assay in its clinical laboratories as a key part of its pharma services offering for clinical trials."
Angle's share price rose by 1.2% to 129.00 pence each in London on Friday morning.
By Elizabeth Winter; elizabethwinter@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
